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1892Objectives: We aimed to compare the performance and midterm survival of transcutaneous aortic valve
replacement (TAVR) and surgically implanted stentless aortic valve replacement (SAVR) for severe aortic
stenosis in patients anticipated to have patient–prosthesis mismatch (PPM).
Methods: A retrospective analysis was performed of 86 and 49 consecutive TAVR and SAVR patients with
severe aortic stenosis and calculated minimal effective orifice area larger than the best projected effective orifice
area. Cox hazard analyses were used to assess the effect of TAVR versus SAVR on outcome.
Results: The peak and mean transprosthetic gradient at discharge were lower (P< .001 for both) in the
TAVR group. Mild or greater aortic regurgitation was more frequent in the TAVR group (61% vs 7%;
P<.0001). At 3 months of follow-up, the mean gradient in the TAVR group was similar to that of the SAVR
group but the prevalence of aortic regurgitation was still higher. The unadjusted 3-year survival rate was superior
in the SAVR versus TAVR group (91.6%  4% vs 67.0%  7%; P ¼ .01). Adjustments for both age and
comorbidity resulted in loss of the difference in mortality between the 2 groups.
Conclusions: In patients with anticipated PPM, TAVR offers an immediate lower incidence of PPM than
SAVR but a greater prevalence of aortic regurgitation. The differences in transaortic gradients became
nonsignificant 3 months postoperatively. The question of whether TAVR is a suitable substitute for SAVR in
patients with anticipated PPM, in particular, those who are older and sicker, warrants additional investigation.
(J Thorac Cardiovasc Surg 2014;147:1892-9)Patient–prosthesis mismatch (PPM) occurs when the
effective orifice area (EOA) of a normally functioning
prosthesis is too small in relation to the patient’s body
size, resulting in an abnormally high postoperative
gradient.1 Aortic valve replacement (AVR) in patients with
a small aortic annulus for the body surface area (BSA) has
been associated with a high incidence of PPM,2-4 which
has been associated with increased mortality, more
congestive heart failure, and worse functional capacity.5
The most widely validated parameter for identifying PPM
is the calculated EOA, indexed by the patient’s BSA6
(iEOA). When the aortic iEOA is less than 0.85 cm2/m2,
the patient is considered to have moderate PPM, and when
the aortic iEOA is less than 0.65 cm2/m2, the patient has
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The Journal of Thoracic and Cardiovascular Surprosthesis to be inserted1 is calculated by multiplying the
patient’s BSA by 0.85 and compared with the projected
EOA, defined by the size of the patient’s annulus diameter
and the manufacturer’s reference value. Whenever the min-
imal EOA is more than the projected EOA, PPM is antici-
pated. For anticipated PPM, several solutions have been
proposed, from which AVR with stentless valves (SAVR)
has gained popularity owing to the excellent iEOA, low
transprosthetic gradients, and greater left ventricular (LV)
mass regression.7 Recently, transcatheter aortic valve
replacement (TAVR) has emerged as an alternative to AVR
for high-risk patients with aortic stenosis,8 with respect to
relief of stenosis and postprocedural valve hemodynamics.9
We sought to compare the hemodynamics and early and
midterm outcomes in patients with anticipated PPM, who
were treated with either SAVR or TAVR, at our institution.METHODS
Eligibility and Projected iEOA
Patients were eligible for analysis if they had severe aortic stenosis and
were anticipated to have at least moderate PPM according to their BSA and
annulus size, assuming a stented bioprosthesis were implanted. To define
eligibility, we used the following strategy before aortic valve intervention.3
We calculated the patient’s BSA; calculated the minimal required EOA by
multiplying the BSA by 0.85 cm2/m2; and compared the result obtained in
the second step with that of the projected EOA.10 Patients were eligible forgery c June 2014
Abbreviations and Acronyms
AR ¼ aortic regurgitation
AVR ¼ aortic valve replacement
BSA ¼ body surface area
CI ¼ confidence interval
EOA ¼ effective orifice area
iEOA ¼ calculated EOA, indexed by the patient’s
body surface area
HR ¼ hazard ratio
LV ¼ left ventricular
NYHA ¼ New York Heart Association
PPM ¼ patient–prosthesis mismatch
SAVR ¼ stentless aortic valve replacement
TAVR ¼ transcatheter aortic valve replacement
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projected EOA for any type of available stented bioprosthesis.
SAVR Procedure
All SAVR patients underwent AVR with a Freestyle stentless
bioprosthesis (Medtronic Inc, Minneapolis, Minn). The operative
technique has been previously described.11 In brief, all operations were
performed through a standard midline sternotomy. Excision of the native
aortic valve and annular debridement were followed by sizingwith the sizer
provided for the Freestyle stentless bioprosthesis valve, with consideration
given to the size at both the annulus and the sinotubular ridge. The Freestyle
valve was then inserted in the subcoronary position or as a full root
replacement. When subcoronary insertion was applied, a 2-layer suture
technique was used.
TAVR Procedure
All TAVR procedures were performed in patients with severe sympto-
matic aortic stenosis with a balloon-expandable valve (Edwards SAPIEN,
Edwards LifeSciences, Inc, Irvine, Calif) or a self-expandable valve
(CoreValve, Medtronic, Inc) through the transfemoral approach with the
patient under local anesthesia. The valve prosthesis size was selected on
the basis of the aortic annulus measurements obtained by transesophageal
echocardiography performed before the procedure. For the balloon-
expandable valve, a 23-mm valve was selected if the aortic annulus was
17 to 21 mm, with a 26-mm valve selected, if the aortic annulus was
22 to 25 mm. For the self-expandable valve, a 26-mm valve was selected
if the aortic annulus was 20 to 23 mm, with a 29-mm valve selected
if the aortic annulus was 23 to 27 mm. Balloon aortic valvuloplasty was
performed in all patients before valve implantation. Immediately after
valve deployment, evaluation of the presence and severity of aortic
regurgitation (AR) was assessed visually by determination of the relative
amount of radiographic contrast medium in the ventricle after injection
into the proximal aorta and classified using a scale of 0 to 4. Balloon
dilation was performed in cases of significant paravalvular AR, defined
as AR of grade 2 or greater. After balloon dilation, the presence and degree
of AR was again evaluated, and a second dilation was performed at the
discretion of the physician.
Study Design
The present study was a nonrandomized, retrospective, single-center
study. Because it was judged to be a low-risk, retrospective analysis, the
institutional review board approved wavering of informed consent. The
study was designed with 2 aims. First, to assess the hemodynamicThe Journal of Thoracic and Carperformance of TAVR compared with SAVR in terms of the transprosthetic
gradient and prevention of severe PPM in patients identified to have a high
risk of PPM. Second, the TAVR and SAVR patients were compared for
midterm survival.
The first step was to identify the TAVR cohort. From January 2009 to
December 2011, 200 TAVR procedures were performed in patients with
severe aortic stenosis at our institution. In 86 patients, the calculated
minimal EOA was larger than the best projected EOA10 for any type of
available stented bioprosthesis, and these patients were considered eligible
for analysis (TAVR cohort). Second, we compared the TAVR patients
with 49 consecutive patients (SAVR cohort) with severe aortic stenosis,
identified from a prospective registry database of all 192 patients who
had undergone SAVR with a stentless Freestyle bioprosthesis (Medtronic,
Inc) during the same period, who were similar to the TAVR group for the
predefined inclusion characteristics. The patients in both cohorts
(TAVR and SAVR) had undergone AVR contemporaneously. The presence
of a bicuspid aortic valve was a contraindication for TAVR, and we,
therefore, also excluded patients with a bicuspid valve from the SAVR
cohort. All echocardiographic data were collected at baseline, before
hospital discharge, and at the 3-month follow-up examination. Survival
was calculated from AVR (either TAVR or SAVR) until the date of the
last clinical encounter for all patients.
Baseline, Follow-up, and Clinical Outcomes
The baseline clinical data were collected by interviewing the patients
and reviewing their medical files. Coexisting conditions were evaluated
using the Charlson comorbidity index,12 which contains different
categories of comorbidities. Clinical follow-up data were obtained by a
review of the medical records, surveys, and telephone interviews. The
cause of death was determined by a review of all medical records,
telephone interviews, and death certificates. The event used as the endpoint
was all-cause mortality.
Echocardiography
Two-dimensional transthoracic echocardiography was performed in a
standard manner using the same equipment (iE33, Philips Medical
Systems, Bothell, Wash).
The ejection fraction was calculated using the Simpson method,13 and
the LV diameters, interventricular septal and posterior wall width, LV
mass, relativewall thickness, LV stroke, and cardiac output were calculated
as recommended.13
The severity of aortic stenosis was defined by the maximal velocity
across the aortic valve, the mean pressure gradient, and the aortic valve
area, calculated by the standard continuity equation (maximal velocity,
>4 m/s; mean gradient,>40 mm Hg; and aortic valve area,<1.0 cm2).
Grading of AR after TAVR or SAVR was performed in a semiquantitative
fashion, using color Doppler imaging, according to the number of jets, the
jet width in the central jets, and the circumferential extent of the jet in
paravalvular AR using the parasternal long-axis, parasternal short-axis,
and apical long-axis views. AR was classified as follows: 0, absent; 1,
trivial or mild; 2, mild-to-moderate; 3, moderate; and 4, severe. To estimate
the effective regurgitant orifice (EOA) after TAVR, we used the methods
described by Clavel et al.14
Statistical Analysis
Continuous normally distributed parameters are presented as the mean
 standard deviation and were compared using the Student t test or paired
t test, as appropriate. Ordinal and/or non-normally distributed data are
presented as the median and first and third quartiles and were compared
using the Wilcoxon rank sum or Wilcoxon signed rank test. Categorical
data were compared between groups using the chi-square test or Fisher’s
exact test, whenever the expected values in any of the cells of a contingency
table were less than 5. Unadjusted and adjusted Cox proportional hazardsdiovascular Surgery c Volume 147, Number 6 1893
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calculation of the hazard ratios (HRs) and 95% confidence intervals (CIs).
Event distributions were calculated using the Kaplan-Meier method and
compared using the log-rank test. All P values were 2-sided, and P<.05
were considered statistically significance. All data were analyzed using
the JMP system software, version 9.0 (SAS Institute, Inc, Cary, NC), and
Statistical Package for Social Sciences, version 17.0, software package
(SPSS Inc, Chicago, Ill).
RESULTS
Baseline Characteristics
The baseline characteristics of the enrolled patients
(n ¼ 135) stratified by use of TAVI or SAVR are listed in
Table 1. The mean age of entire cohort was 79.0  7 years,
and 33% were men. The cause of AS was degenerative-
calcific in all patients, and all patients were symptomatic
(New York Heart Association [NYHA] class II or greater).
The median and first and third quartiles for logistic
EuroSCORE II was 5.6 and 3.7 and 9.0 and for the Charlson
comorbidity index was 5.9 and 4.9 and 6.8. Previous
coronary bypass had been performed in 3 patients (6%)
in the SAVR group and 14 (16%) in the TAVR group
(P ¼ .2). None of the procedures in either group was
performed emergently or because of a critical state, and
none of the patients in either group needed an intra-aortic
balloon pump before the procedure. The baseline
echocardiographic data for the entire study population
showed the following mean values: left ventricular ejection
fraction, 56.2%  7%; aortic peak pressure gradient,
77.7  25 mm Hg; aortic mean pressure gradient,
46.3  16 mm Hg; and aortic valve area, 0.66  0.16 cm2.
A comparison between groups verified that the BSA,
gender, LV outflow tract diameter, and peak and mean
pressure gradients were similar. Additional echocardio-
graphic Doppler parameters, such as ejection fraction,
diastolic parameters, and right ventricular systolic pressure,
displayed no difference between the 2 groups (Table 1). The
TAVR patients were older, with a greater NYHA functional
class and higher logistic EuroSCORE II and Charlson
comorbidity scores.
Operative Outcomes and Operative Mortality
The postprocedural outcomes for all patients stratified by
procedure are listed in Table 2. The valve types and sizes
in the TAVR group were Edwards SAPIEN (Edwards
LifeSciences) 23 mm in 6 patients and 26 mm in 3 patients,
CoreValve 26 mm (Medtronic, Inc) in 45 patients and 29
mm in 32 patients. The valve sizes in the SAVR group
were 21 mm in 6 patients, 23 mm in 14 patients, 25 mm
in 17 patients, 27 mm in 8 patients, and 29 mm in 4 patients.
Aortic root enlargement and Bentall procedures were not
used in the SAVR patients. In patients with SAVR, the
cardiopulmonary bypass time was 122.9  45.5 minutes,
and the aortic crossclamp time was 96.7  36.8 minutes.
In 46 of the SAVR patients (94%), implantations were1894 The Journal of Thoracic and Cardiovascular Sursubcoronary, and in 3 (6%), concomitant aortic surgery
on the thoracic aorta was performed. The rate of interven-
tion for associated coronary artery disease, specifically
concomitant coronary bypass and SAVR versus adjuvant
percutaneous coronary intervention before TAVR was not
different (23 [47%] vs 47 [55%], respectively; P ¼ .4).
The median duration of the length of stay was 7 days
(6 vs 9 days, respectively; P ¼ .3) and was not different
between the 2 groups. Of the 135 patients, 4 died before
discharge, 3 (3%) in the TAVR group and 1 (2%) in the
SAVR group (P ¼ .6). All the patients who died in hospital
died during the 30-day period after surgery, but none died
during the AVR surgery. The cause of early postoperative
mortality was acute left heart failure with cardiogenic shock
in 1 patient and sepsis in 2 patients in the TAVR group and
multiorgan failure in the SAVR patient. The only difference
between the groups in terms of early complications was a
greater rate of need for a new pacemaker in the TAVR group
(16% vs 2%; P ¼ .01).
Doppler Echocardiographic Data
The Doppler echocardiographic data at hospital
discharge are listed in Table 2. The peak and mean
transprosthetic gradient were lower (P< .0001 for both)
at discharge in the TAVR group than in the SAVR group
and the aortic valve area, aortic valve area index, and
dimensionless left ventricular to transprosthetic velocity
integral ratio were larger (P<.0001 for all). The incidence
of PPM before discharge was greater (P ¼ .002) in the
SAVR group (30%) than in the TAVR group (6%). At least
mild AR was present in 61% of the TAVR patients
compared with 7% of the SAVR patients, immediately after
the procedure (P<.0001). AR was paravalvular in all the
cases in the TAVR group. The Doppler echocardiographic
data at 3 months of follow-up are listed in Table 2. No
significant changes were found in the mean transvalvular
gradient, aortic valve area, or aortic valve area index
between hospital discharge and 3 months of follow-up in
the TAVR patients (P> .4 for all variables). In contrast,
the peak transvalvular gradient (P ¼.04) and mean
transvalvular gradient (P ¼ .05) exhibited a significant
reduction and the aortic valve area had increased
(P¼ .04) in the SAVR patients compared with at discharge.
At 3 months of follow-up, no significant differences were
observed regarding all the hemodynamic variables between
the TAVR and SAVR groups (P>.1 for all variables). The
incidence and degree of AR remained similar to those at
hospital discharge in both groups, with a greater incidence
of mild AR or greater in the TAVI group (56%) than in
the SAVR group (0%).
All-Cause Mortality
The follow-up period was significantly longer in
the SAVR group than in the TAVR group (3.6  1.7 yearsgery c June 2014
TABLE 1. Baseline and echocardiographic characteristics of patients
with severe aortic stenosis and anticipated PPM overall and stratified
by TAVR or SAVR
Variable
TAVR
(n ¼ 86)
SAVR
(n ¼ 49)
P
value
Demographic parameters
Weight (kg) 75.6  14.5 79.9  15.2 .1
Height (cm) 163.0  8.2 166.2  10.4 .07
BMI (kg/m2) 28.4  4.9 28.9  5.2 .6
BSA (m2) 1.81  0.18 1.86  0.20 .2
Age (y) 82.4  5.05 73.0  7.77 <.001
Male gender (n) 28 (32) 16 (32) .9
Echocardiographic parameters
EF (%) 56.8  6.5 55.0  7.9 .2
IVSd (cm) 1.3  0.2 1.4  0.3 .3
LVEDD (cm) 4.4  0.7 4.7  0.7 .02
PWd (cm) 1.2 (1, 1.3) 1.2 (1.1, 1.3) .5
LV mass (g) 219.7  65 252.5  83 .02
RWT 1.05  0.4 0.93  0.3 .05
LVESD (cm) 2.7  0.7 3.0  0.7 .01
LVOT diameter (cm) 1.95  0.11 1.94  0.13 .7
Stroke volume (mL) 64 (57, 75) 68 (49, 84) .5
E wave (cm/s) 108.4  38.3 97.0  32.3 .09
E deceleration time (ms) 254 (172, 328) 203 (180, 254) .4
Awave (cm/s) 106.7  30.01 95.6  30.3 .07
Transaortic Vmax (cm/s) 439.8  57.3 416.4  89.2 .1
Peak pressure transaortic
gradient (mm Hg)
78.8  21.3 75.5  31.6 .5
Mean pressure transaortic
gradient (mm Hg)
47.9  13.7 43.1  19.2 .2
AVA (cm2) 0.64  0.15 0.71  0.17 .2
RA pressure (mm Hg) 5 (5, 10) 5 (5, 5) .01
Systolic pulmonary pressure
(mm Hg)
40.8  16.4 37.1  12.2 .2
Mitral regurgitation .1
None 24 (28) 16 (33)
Mild 55 (64) 30 (61)
Moderate 6 (7) 3 (6)
Severe 1 (1) 0 (0)
AR .05
None 34 (39) 22 (45)
Mild 49 (57) 22 (45)
Moderate 3 (4) 3 (6)
Severe 0 (0) 2 (4)
Clinical parameters
Preoperative critical state (n) 0 0 NS
Recent MI (n) 0 0 NS
Emergency surgery (n) 0 0 NS
Concomitant coronary
intervention (n)
47 (55) 23 (47) .4
Surgery on thoracic aorta (n) 0 3 (6) .05
Bicuspid aortic valve (n) 0 0 NS
NYHA class (%) .01
I 0 0
II 0 8
III 75 65
IV 25 27
(Continued)
TABLE 1. Continued
Variable
TAVR
(n ¼ 86)
SAVR
(n ¼ 49)
P
value
Atrial fibrillation (n) 15 (17) 8 (16) .9
Previous stroke (n) 7 (8) 2 (4) .5
Previous CABG (n) 14 (16) 3 (6) .1
Creatinine (mg/dL) 1.19  0.67 1.16  0.29 .7
PVD (n) 13 (15) 3 (6) .2
CVA (n) 6 (7) 4 (8) 1.0
COPD (n) 22 (25) 26 (53) .002
Diabetes (n) 25 (29) 16 (33) .7
Solid tumor (n) 9 (10) 1 (2) .09
Logistic EuroSCORE II 6.5 (4.3, 10.5) 4.6 (3.1, 7.3) .003
Charlson score 6.3 (5.3, 7.3) 5.3 (4.5, 6.3) .0009
Data presented as mean  standard deviation, n (%), or median (first, third quartile).
PPM, Patient–prosthesis mismatch; TAVR, transcutaneous aortic valve replacement;
SAVR, stentless surgical aortic valve replacement; BMI, body mass index; BSA, body
surface area; EF, ejection fraction; IVSd, interventricular septum diameter; LVEDD,
left ventricular end-diastolic diameter; PWd, posterior wall diameter; NS, not signifi-
cant; LV, left ventricular; RWT, relative wall thickness; LVESD, left ventricular
end-systolic diameter; LVOT, left ventricular outflow tract; Vmax, maximal velocity;
AVA, aortic valve area; RA, right atrium; AR, aortic regurgitation; MI, myocardial
infarction; NYHA, New York Heart Association; CABG, coronary artery bypass
grafting; PVD, peripheral vascular disease; CVA, cerebrovascular accident; COPD,
chronic obstructive pulmonary disease.
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The unadjusted 3-year survival rate was lower in the
TAVR group than in the SAVR group (67.0%  7.7% vs
91.6% 4.0%; P¼ .01). Cox proportional hazard analysis
for parameters associated with all-cause mortality showed
that the use of TAVR compared with SAVR was associated
with increased mortality (HR, 3.5; 95% CI, 1.3-11.0 for
TAVR; P ¼ .01; Figure 1). The clinical parameters
significantly associated with increased mortality were age
(HR, 1.02; 95% CI, 1.02-1.17 for each year; P ¼ .005)
and a higher Charlson comorbidity index (HR, 1.46; 95%
CI, 1.08-2.0 for each grade; P ¼ .01). Trends were seen
for increased mortality with NYHA class greater than II
before the procedure (HR, 1.9; 95% CI, 0.8-4.8; P ¼ .1),
chronic obstructive pulmonary disease (HR, 2.5; 95% CI,
0.94-5.9; P ¼ .06). The logistic EuroSCORE II, previous
coronary artery bypass grafting, renal disease, diabetes,
valve size, and BSA did not affect the overall mortality rates
(P > .3 for all). The preprocedural echocardiographic
parameters associated with increased mortality were lower
peak and mean transprosthesis gradients (HR, 0.98 and
0.97; 95%CI, 0.96 and 0.94-0.99 for an increase in gradient
by 1 mm Hg, respectively; P ¼ .02 for both]). Neither the
aortic valve area, diastolic parameters, qualitatively
estimated mitral regurgitation, nor tricuspid regurgitation
peak velocity were associated with midterm mortality
(P>.3 for all).
Table 3 and Figure 1 show the results of adjusted Cox
proportional hazard analyses for all-cause mortality in all
patients. Because of the small sample size and the low
number of events, we restricted the explanatory variablesdiovascular Surgery c Volume 147, Number 6 1895
TABLE 2. Clinical and echocardiographic postintervention outcomes
after TAVR versus SAVR
Variable
TAVR
(n ¼ 86)
SAVR
(n ¼ 49)
P
value
Surgical outcome
Valve size (mm) 25 (23, 26.5) 26 (26, 29) <.001
Bypass time (min) None 122.9  45.5 NA
Aortic crossclamp time (min) None 96.7  36.8 NA
Concomitant coronary
intervention (n)
47 (55) 23 (47) .4
Length of stay (d) 7 (5, 9) 7 (6, 10) .4
Early mortality (30 d) 3 (3.5) 1 (2.0) .6
Need for new pacemaker (n) 14 (16) 1 (2) .01
CVA (n) 2 (2) 1 (2) 1.0
Tamponade (n) 2 (2) 1 (2) 1.0
After MI (n) 0 0 1.0
Acute renal failure (n) 3 (3) 4 (8) .2
Infection (n) 10 (11) 3 (6) .4
Echocardiographic parameters
before discharge
Peak pressure gradient (mm Hg) 16.3  6.7 23.8  9.09 <.001
Mean pressure gradient (mm Hg) 9.08  3.62 12.5  4.83 .0002
AV Vmax (cm/s) 195.6  38.8 245.8  70.1 <.001
LVOT Vmax (cm/s) 122.5  36.5 114.7  23.6 .2
LVOT VTI (cm) 23.52  6.43 21.68  7.65 .2
Dimensionless index 0.63  0.18 0.49  0.14 .0001
AVA (cm2) 1.88  0.44 1.43  0.41 <.0001
AVA index (cm2/m2) 1.05  0.25 0.78  0.24 <.0001
Moderate PPM (n) 15 (17) 31 (74) <.0001
Severe PPM (n) 5 (6) 13 (30) .001
AR (%) <.0001
None 39 93
Mild 61 7
Moderate 0 0
Severe 0 0
90-d Postprocedural
echocardiographic parameters
Peak pressure gradient (mm Hg) 14.9  6.6 19.2  8.2 .2
Mean pressure gradient (mm Hg) 8.4  3.9 9.0  4.24 .7
AV Vmax (cm/s) 190.2  42.4 234.1  67.2 .1
LVOT Vmax (cm/s) 116.2  27.9 103.4  30.3 .4
LVOT VTI (cm) 23.1  5.6 37.1  37.4 .4
Dimensionless index 0.63  0.17 0.51  0.22 .1
AVA (cm2) 1.88  0.46 1.71  0.81 .7
AVA index (cm2/m2) 1.05  0.27 0.91  0.42 .5
Moderate PPM (n) 17 (19) 8 (16) .8
Severe PPM (n) 4 (5) 4 (8) .5
AR (%) <.0001
None 44 100
Mild 54 0
Moderate 1 0
Severe 1 0
Data presented as median (first, third quartile), mean  standard deviation, n (%), or
%. AV, Aortic valve; VTI, velocity time integral; PPM, patient–prosthesis mismatch;
TAVR, transcutaneous aortic valve replacement; SAVR, stentless surgical aortic valve
replacement; LVOT, left ventricular outflow tract; AVA, aortic valve area; AR,
aortic regurgitation; MI, myocardial infarction; CVA, cerebrovascular accident;
NA, not applicable.
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hazard analysis for any echocardiographic parameter did
not affect the association between higher mortality and
TAVR (P> .4 for all). However, the adjustments for age
or comorbidity weakened the association between TAVR
and increased mortality (Figure 1), and the adjustment for
both age and comorbidity resulted in survival similar to
that of TAVR (Figure 1), although with a continued trend
favoring SAVR.
DISCUSSION
Our results have shown that in patients identifiedashavinga
high risk of developing PPM, TAVR is associatedwith a lower
immediate incidence of PPM but greater incidence of AR
comparedwith SAVR.At 3months of follow-up, the hemody-
namic differences become nonsignificant. The early superior
transprosthetic gradients obtainedwithTAVRdidnot translate
into better survival. The SAVR patients had superior long-
term survival in the nonadjusted analysis, that was partially
corrected by adjustment for both age and comorbidities.
PPM in TAVR Versus SAVR
Numerous studies have recognized the significance of
achieving optimal hemodynamic result after AVR.2 The
present study is the first to evaluate the incidence of PPM
and compare survival after TAVR versus SAVR in a selected
group of patients with anticipated PPM. We found a low
early incidence of severe PPM (5%) with TAVR, consistent
with a previous report,15 that was lower than that with the
use of the stentless valve, as previously described.9,16 The
hemodynamic performance of the stentless bioprostheses
continued to improve in the 3 months after surgery,
converting the significant early difference in the incidence
of PPM between SAVR and TAVR to an insignificant
trend after 3 months. These results are in accordance with
reports by other groups,17,18 showing comparable rates of
severe PPM among patients with a small aortic root
undergoing SAVR or TAVR.
The possible reasons for the early superior performance
of TAVR compared with the stentless valve might be that
valve sizing during SAVR is limited by the dimensions of
the aortic annulus. In contrast, TAVR is systematically per-
formed with an oversized valve, leading to some distension
of the aortic annulus to accommodate the valve. In addition,
the unique design of the TAVR prosthesis provides minimal
obstruction to blood flow.9 In summary, our findings suggest
that in selected patients anticipated to have PPM, compared
with SAVR, TAVR provides better immediate results, which
become comparable after 3 months.
Midterm Mortality and Outcomes
In patients with anticipated PPM, the procedural risk of
SAVR and TAVR is reasonable. The significant decline ingery c June 2014
FIGURE 1. Adjusted Cox hazard survival plots stratified by transcutaneous aortic valve replacement (TAVR) versus stentless aortic valve replacement
(SAVR). A, Plot showing that unadjusted survival was significantly better with SAVR. B and C, Plots showing that the differences in survival became
nonsignificant when adjusting for age or Charlson comorbidity index, respectively. Note, a trend was seen for improved survival with SAVR when adjusting
for either age or comorbidity index alone. D, Adjustment for both age and comorbidity showed similar survival in both SAVR and TAVR.
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Dmidterm survival in patients with a low stroke volume and
low transaortic gradient and the trend for increased
mortality in patients with NYHA class greater than II might
suggest that we should intervene at an earlier stage before
patients have developed severe cardiac dysfunction and
are only mildly symptomatic.
Survival was better with SAVR than with TAVR, in
discordance with the superior early transaortic gradients
of TAVR and lower incidence of early PPM. The increased
mortality observed in the TAVR patients could possibly be
explained by the combination of several factors. First, andThe Journal of Thoracic and Carmost important, the TAVR patients were older and more
ill, adversely affecting their midterm survival. Importantly,
when adjusting or matching for the differences in both age
and comorbidities between the groups, the survival was
similar, as described in previous reports.19 However, the
trend for improved survival in SAVR was not entirely
corrected by matching for typical risk factors. Thus, we
believe that TAVR can be considered as a possible solution
in older patients with significant comorbidities and
anticipated PPM but should not be used as the first line of
therapy in patients with a low risk of surgical AVR. Second,diovascular Surgery c Volume 147, Number 6 1897
TABLE 3. Adjusted analysis with Cox proportional hazards models of midterm mortality
Variable
TAVR versus SAVR,
nonadjusted Peak aortic pressure Age Charlson index Charlson index and age
TAVR vs SAVR 3.5 (1.3-11.0; .01*) 4.5 (1.6-15.3; .003*) 1.9 (0.6-7.2; .3) 2.5 (0.95-8.1; .07) 1.6 (0.5-5.9; .4)
Age (y) — — 1.06 (1.0-1.16; .05*) — 1.09 (1.01-1.19; .03*)
Male gender — — — — —
Charlson comorbidity index — — — 1.4 (1.02-1.9; .03*) 1.4 (1.01-1.8; .05*)
EF (%) — — — — —
End systolic diameter (cm) — — — — —
Peak aortic systolic pressure
(mm Hg)
— 0.97 (0.95-0.99; .005*) — — —
Mild or greater AR after
procedure
— — — — —
Data presented as hazard ratio (95% confidence interval; P value). TAVR, Transcutaneous aortic valve replacement; SAVR, stentless surgical aortic valve replacement; EF, ejection
fraction; AR, aortic regurgitation. *Statistically significant.
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AR after the procedure, which has been shown to adversely
affect the midterm outcome.20 The greater prevalence of
AR after TAVR could offset the beneficial effect on survival
of less PPM. Third, although PPM has been shown to
adversely affect survival, there is likely a complex interplay
between different patient-related factors and their effect on
outcome. PPM decreases survival mainly in younger
patients21 and in patients with a poor ejection fraction,21
pre-existing left ventricular dysfunction,22 and severe
concentric hypertrophy,23 all of which were underrepre-
sented in our cohort, which might have ‘‘diluted’’ the
positive effect of lesser early PPM in the TAVR group on
the overall outcome.
Study Limitations
The study cohort was small, and the differences in age
and comorbid conditions were large between the TAVR
and SAVR groups. Because of the relatively small number
of patients, follow-up of less than 3 years for most TAVR
patients, and the small number of events, we lacked the
statistical power to predict the long-term outcomes, and
some potentially important associations (NYHA, logistic
EuroSCORE II) did not reach significance. Although
SAVR offers good hemodynamic outcomes, it has never
demonstrated superior outcomes compared with the routine
stented valves. Our local routine has been to perform SAVR
in all patients with expected PPM whenever surgical AVR
was planned; thus, we were unable to analyze whether
TAVR performs better or worse than SAVR in patients
with expected PPM. Furthermore, the aortic crossclamp
time was prolonged compared with the Society of Thoracic
Surgeons mean crossclamp time, possibly owing to the
complexity of SAVR, which might have biased our results
in favor of TAVR.
CONCLUSIONS
In patients with anticipated PPM, TAVR offers immedi-
ate lower transaortic gradients than SAVR but a greater1898 The Journal of Thoracic and Cardiovascular Surprevalence of AR. The differences in the transaortic
gradients became nonsignificant 3 months after surgery.
Nonadjusted survival was superior in the SAVR group but
comparable when adjusted for both age and comorbidity.
The question of whether TAVR is a suitable substitute for
SAVR in patients with anticipated PPM, in particular, those
who are older and sicker, warrants additional investigation.References
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